ImmunoBrain Checkpoint is pioneering a novel approach to treating neurodegenerative diseases, particularly Alzheimer’s, by leveraging the body's peripheral immune system. Traditionally, the focus has been on the Central Nervous System (CNS) as an isolated entity, leading to treatment strategies that primarily target the brain. However, ImmunoBrain posits that the peripheral immune system, especially through immune checkpoint pathways like PD-1/PD-L1, plays a critical role in brain health. By activating this system, the company aims to enhance the immune response, facilitating the recruitment of immune cells to the brain. This recruitment is intended to reduce neuroinflammation, clear toxic proteins, and support neuronal repair, thereby potentially transforming the treatment landscape for neurodegenerative disorders.

The company’s lead program, IBC-Ab002, is currently undergoing a Phase 1b clinical trial to evaluate its safety and efficacy in patients with early Alzheimer’s disease. This trial is designed as a randomized, double-blind, placebo-controlled study, assessing various doses of IBC-Ab002 administered intravenously. The research is grounded in over two decades of studies from Professor Michal Schwartz's lab, which have demonstrated that transient blockade of the PD-1/PD-L1 pathway can rejuvenate the adaptive immune response, leading to significant cognitive improvements in preclinical models. ImmunoBrain is committed to translating these promising findings into clinical applications, aiming to provide effective, disease-modifying treatments for those affected by neurodegenerative diseases.

Israel

ImmunoBrain Checkpoint (IBC) is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. IBC’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease.

IBC's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.

ImmunoBrain Checkpoint

Company Details